TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: plasma cortisol levels at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: median daily OCS dosage reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median cumulative OCS dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for moderate/severe OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IFABP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEG recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to treatment for bipolar disorder
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: teeth with complete healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to the histamine test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative permanent neurologic morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: restenosis rates
Endpoint domain: Adverse events/effects
Primary endpoint: nadir oxyhaemoglobin saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Narrower QRS complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: More synchronic ventricular systole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Less negative effect on heart function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvements in FDA items related to speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive dysfunction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Impairment of everyday functioning due to physical problems
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnosis of hepatitis C virus infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: overall improvement according to the BPRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discontinuations of treatment due to lack of drug efficacy or adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: completion of 6 weeks of therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk of AF/AFL recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Median time to first AF/AFL recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in 2-h insulin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to achieving good/moderate EULAR response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-week peak VO(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma total carnitine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean longitudinal displacement under load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean horizontal displacement under load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: contact area under load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Get‐Up‐and‐Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracellular homocysteine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical occurrence or deterioration of overt heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Moderate to severe retinal hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete relief from symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection delay of VT/VF episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Procedural skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Teamwork behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined symptom‐medication score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly UI episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient perception of treatment benefit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resolution of sore throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disappearance of pharyngeal erythema and exudate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interstitial glucose incremental area under the curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CRCS adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk factor score for metabolic syndrome components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of interstitial fibrosis and tubular atrophy (IF/TA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: freedom from disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes remission
Endpoint domain: Mortality/survival
Primary endpoint: Diagnostic accuracy of NBI-Z for gastric atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of ischaemic heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptomatic anastomotic leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Anastomotic‐vaginal fistula (AVF)
Endpoint domain: Adverse events/effects
Primary endpoint: Need for unscheduled re‐operation
Endpoint domain: Adverse events/effects
Primary endpoint: Mean infection-free survival of catheters
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of CRB within 6 weeks
Endpoint domain: Adverse events/effects
Primary endpoint: conduction recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sperm production rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: First phase insulin secretion (FISP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Post-prandial symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of injurious falls
Endpoint domain: Mortality/survival
Primary endpoint: incidence of fractures
Endpoint domain: Mortality/survival
Primary endpoint: false-alarm responses in No-Go trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of randomised participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: User awareness of NHGDoc functions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: User attitude towards CDSSs
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Barriers to using NHGDoc
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: HR-HPV prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Seroconversion rate for A/H1N1 strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titre for A/H1N1 strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of active disease
Endpoint domain: Adverse events/effects
Primary endpoint: duration of post-operative leucocytosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PHA-induced lymphocyte proliferative responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anterior capsule tear rates
Endpoint domain: Adverse events/effects
Primary endpoint: phacoemulsification time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: overall BSS volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of whole mouth plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak pressure gradients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: composite end point of death, stroke, or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Diagnostic accuracy of scintimammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean RR interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High frequency heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinically significant reductions on depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically significant reductions on hopelessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically significant reductions on suicide ideation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically significant reductions on posttraumatic stress symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum HDL-C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serum creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Endoscopic grading score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptom score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Combined cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hospital readmission due to recurrent ischemic angina
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: abdominal discomfort ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased muscle pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased pressure‐pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved joint position sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants with appropriate intradermal wheal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of NPOU or NPSU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean volume receiving 100% of prescription dose (V(100))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean dose to 90% of the prostate (D(90))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose to 10% of urethra (urethra D(10))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychosocial Summary scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical Health Summary scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Randomization acceptance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Moist desquamation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Inter-observer agreement for CTC acute skin scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optical density values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barthel Index score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of ipsilateral stroke at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: overall stress scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Score (QoLS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency and intensity of hot flushes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Kupperman index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of glycated haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of hypoglycaemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Deterioration in FHSI-8
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Deterioration in PS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in plasma total homocysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of cardiac complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in plaque scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Reduction in gingival scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: PIPP scores after heel-stick
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive scores at 12 months corrected age
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Corneal cylinder measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate (HR) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Brief Psychiatric Rating Scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial function assessed by flow‐mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative hemoglobin decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean chest tube stay duration
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prolonged air leak occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Fetal heart rate accelerations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fetal heart rate decelerations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum low-density lipoprotein cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perceived general bowel health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of hypoglycemia episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in nausea/vomiting
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Influenza-specific IgA antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Influenza-specific IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Influenza-specific IgM antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: subgingival counts of Fusobacterium nucleatum and Prevotella intermedia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clearance of psoriatic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in anxiety and depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: KABC sequential processing performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KABC simultaneous processing performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BRIEF and ADHD‐RS‐IV ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant satisfaction with training format
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean time required for intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean serum homocysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean flow velocity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemoglobin saturation increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ridge height reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of very-low-density lipoprotein (VLDL) particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of low-density lipoprotein (LDL) particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of high-density lipoprotein (HDL) particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Healthful and unhealthful behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in urinary analytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fall in pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average weeks of headache pain-free
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: percentage of successful responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-rated therapeutic alliance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: wound closure times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: overall times for wound care and closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total cost based on equipment and physician time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Composite of all-cause mortality or rehospitalization for AHF at 180 days
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive performance z‐score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Benefit of Internet-based intervention for depression
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinically significant improvement (MADRS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission (MADRS scores ≤8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary oxalate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Activity product for calcium oxalate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Voice Handicap Index total (VHIt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice Handicap Index emotional (VHIe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice Handicap Index physical (VHIp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year vascular death
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of illicit drug use (lifetime and past 12 months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma norepinephrine (NE) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Discontinuation of treatment due to lack of efficacy
Endpoint domain: Adverse events/effects
Primary endpoint: Metabolic imbalance of ET and CGRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Marked effective and cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total bacteria count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lactobacillus spp. count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: VEGF levels in dental pulp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anxiety scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: QTcd values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes